» Articles » PMID: 23222729

Chlamydia Trachomatis Outer Membrane Complex Protein B (OmcB) is Processed by the Protease CPAF

Overview
Journal J Bacteriol
Specialty Microbiology
Date 2012 Dec 11
PMID 23222729
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported that the Chlamydia trachomatis outer membrane complex protein B (OmcB) was partially processed in Chlamydia-infected cells. We have now confirmed that the OmcB processing occurred inside live cells during chlamydial infection and was not due to proteolysis during sample harvesting. OmcB processing was preceded by the generation of active CPAF, a serine protease known to be able to cross the inner membrane via a Sec-dependent pathway, suggesting that active CPAF is available for processing OmcB in the periplasm. In a cell-free system, CPAF activity is both necessary and sufficient for processing OmcB. Both depletion of CPAF from Chlamydia-infected cell lysates with a CPAF-specific antibody and blocking CPAF activity with a CPAF-specific inhibitory peptide removed the OmcB processing ability of the lysates. A highly purified wild-type CPAF but not a catalytic residue-substituted mutant CPAF was sufficient for processing OmcB. Most importantly, in chlamydial culture, inhibition of CPAF with a specific inhibitory peptide blocked OmcB processing and reduced the recovery of infectious organisms. Thus, we have identified OmcB as a novel authentic target for the putative chlamydial virulence factor CPAF, which should facilitate our understanding of the roles of CPAF in chlamydial biology and pathogenesis.

Citing Articles

Tail-specific protease is an essential virulence factor that mediates the differentiation of elementary bodies into reticulate bodies.

Banerjee A, Jacobs K, Wang Y, Doud E, Toh E, Stein B Infect Immun. 2024; 92(12):e0043624.

PMID: 39535210 PMC: 11629628. DOI: 10.1128/iai.00436-24.


Preclinical screen for protection efficacy of chlamydial antigens that are immunogenic in humans.

Lu C, Wang J, Zhong G Infect Immun. 2023; 91(11):e0034923.

PMID: 37889004 PMC: 10652899. DOI: 10.1128/iai.00349-23.


TargeTron Inactivation of Chlamydia trachomatis Results in a Lipopolysaccharide 3-Deoxy-d-Manno-Oct-2-Ulosonic Acid-Deficient Strain That Is Cytotoxic for Cells.

DeBoer A, Lei L, Yang C, Martens C, Anzick S, Antonioli-Schmit S Infect Immun. 2023; 91(7):e0009623.

PMID: 37255490 PMC: 10353364. DOI: 10.1128/iai.00096-23.


Virulence Protein Pgp3 Is Insufficient To Mediate Plasmid-Dependent Infectivity of Chlamydia trachomatis.

Turman B, Alzhanov D, Nagarajan U, Darville T, OConnell C Infect Immun. 2023; 91(2):e0039222.

PMID: 36722979 PMC: 9933628. DOI: 10.1128/iai.00392-22.


The multiple functions of the numerous secreted proteins: the tip of the iceberg.

Bugalhao J, Mota L Microb Cell. 2019; 6(9):414-449.

PMID: 31528632 PMC: 6717882. DOI: 10.15698/mic2019.09.691.


References
1.
Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G . A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunol. 2010; 185(3):1670-80. DOI: 10.4049/jimmunol.1001240. View

2.
Germain R . The biochemistry and cell biology of antigen presentation by MHC class I and class II molecules. Implications for development of combination vaccines. Ann N Y Acad Sci. 1995; 754:114-25. DOI: 10.1111/j.1749-6632.1995.tb44444.x. View

3.
Zhong G, Liu L, Fan T, Fan P, Ji H . Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med. 2000; 191(9):1525-34. PMC: 2213440. DOI: 10.1084/jem.191.9.1525. View

4.
Eko F, He Q, Brown T, McMillan L, Ifere G, Ananaba G . A novel recombinant multisubunit vaccine against Chlamydia. J Immunol. 2004; 173(5):3375-82. DOI: 10.4049/jimmunol.173.5.3375. View

5.
Zhong G, Reis e Sousa C, Germain R . Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc Natl Acad Sci U S A. 1998; 94(25):13856-61. PMC: 28397. DOI: 10.1073/pnas.94.25.13856. View